The present invention provides compounds of Formula I:
and related compounds as further described herein, and pharmaceutical compositions comprising these compounds. The invention further provides methods to use these compounds and compositions for treating disorders associated with undesired levels of Pim kinase activity, including cancers and autoimmune disorders.
Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders. Particular compounds are of the formula:
[EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASE
申请人:NOVARTIS AG
公开号:WO2012120428A1
公开(公告)日:2012-09-13
The present invention provides compounds of Formula I: (I) and related compounds as further described herein, and pharmaceutical compositions comprising these compounds. The invention further provides methods to use these compounds and compositions for treating disorders associated with undesired levels of Pirn kinase activity, including cancers and autoimmune disorders.
[EN] MST1 KINASE INHIBITORS AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE KINASE MST1 LEURS PROCÉDÉS D'UTILISATION
申请人:LEXICON PHARMACEUTICALS INC
公开号:WO2012121992A1
公开(公告)日:2012-09-13
Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders.